Diabetes Drug Avandia Raises Heart Disease, Death Risk

US senators have linked a diabetes drug to heart disease and death.

They have claimed that the drug Avandia used by tens of thousands of Britons increases the risk of heart problems and could even lead to death, reports the Telegraph. The US Food and Drug Administration (FDA), the medicines safety watchdog, has urged an advisory committee to verify the safety of Avandia.

Diabetes Risk Assessment Calculator
Almost one-third of the people are unaware of the risk factors of diabetes. Find out if you run the risk of diabetes by using Diabetes Risk Assessment calculator.

The British counterpart, the MHRA, said it is "continuously monitoring" the safety of the drug.

In a report, senators Max Baucus and Charles Grassley alleged that the FDA had not banned the drug because it was too "cozy" with drugs firms.

They quoted a memo written by two FDA reviewers, which concluded: "The risks of (Avandia) are serious and exceed those for rival drug Actos."

There was "strong evidence that (Avandia) confers an increased risk of" heart attack and heart failure when compared to Actos, the reviewers said.

A 2007 study, published in the Journal of the American Medical Association, showed that Avandia puts users at a 60 per cent greater risk of heart failure and a 29 per cent greater risk of death than other medication.

HbA1c or A1c Calculator for Blood Glucose
HbA1c calculator calculates average plasma and whole blood glucose levels. A1c test tells your average blood sugar level in the past 3 months and helps check whether your diabetes is in control.

"Americans have a right to know there are serious health risks associated with Avandia and GlaxoSmithKline had a responsibility to tell them. Patients trust drugs companies with their health and their lives," the Telegraph quoted Senator Baucus as saying.

However, a GSK spokesman said it dismissed the report's conclusions.

Prolonged Use of Diabetes Drug 'Avandia' Dangerous
Use of 'Avandia', a drug taken by millions of diabetic patients, for a longer period may be dangerous because of its adverse effect on bones, suggests a new study.

The report "cherry-picks information from documents, which mischaracterises GlaxoSmithKline's comprehensive efforts to research Avandia and communicate those findings to regulators, physicians and patients," the company said.

The company said that it had rigorously studied Avandia's safety and "consistently shared this data with regulators around the world".

GSK said that it "does not condone any effort to silence scientific debate".

Source-ANI
SRM